Pathological stage review is indicated in primary pT1 bladder cancer

BJU International

Volumn 106, Issue 2, 2010, Pages 206-211

  Van Rhijn, Bas W G ^a,d   Van Der Kwast, Theo H ^b,d   Kakiashvili, David M ^a   Fleshner, Neil E ^a   Van Der Aa, Madelon N M ^d   Alkhateeb, Sultan ^a   Bangma, Chris H ^d   Jewett, Michael A S ^a   Zlotta, Alexandre R ^c  

^a Division of Urology   (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

bladder cancer; grade; pathology review; pT1; stage

Indexed keywords

BCG VACCINE;

ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CARCINOMA IN SITU; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 77953844243     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.09100.x     Document Type: Article

References (26)

1. Kirkali Z, Chan T, Manoharan M et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005 66 (Suppl. 6A 4 34
2. Sobin DH, Wittekind Ch eds, TNM Classification of Malignant Tumours, 6th edn.
3. Sylvester RJ, van der Meijden AP, Oosterlinck W et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006 49 : 466 477
4. Fernandez-Gomez J, Solsona E, Unda M et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008 53 : 992 1001
5. van Rhijn BW, Vis AN, van der Kwast TH et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003 21 : 1912 1921
6. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002 168 : 1964 1970
7. Herr HW. Is maintenance Bacillus Calmette-Guérin really necessary? Eur Urol 2008 54 : 971 973
8. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J. EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder. Eur Urol 2008 54 : 303 314
9. Nieder AM, Brausi M, Lamm D et al. Management of stage T1 tumors of the bladder. International Consensus Panel. Urology 2005 66 (Suppl. 6A 108 125
10. Stein JP, Penson DF. Invasive T1 bladder cancer: indications and rationale for radical cystectomy. BJU Int 2008 102 : 270 275
11. Griffiths TR, Charlton M, Neal DE, Powell PH. Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol 2002 167 : 2408 2412
12. Tosoni I, Wagner U, Sauter G et al. Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer. BJU Int 2000 85 : 48 53
13. Bol MG, Baak JP, Buhr-Wildhagen S et al. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J Urol 2003 169 : 1291 1294
14. Witjes JA, Moonen PM, van der Heijden AG. Review pathology in a diagnostic bladder cancer trial: effect of patient risk category. Urology 2006 67 : 751 755
15. Eble J, Sauter G, Epstein J, Sesterhenn I. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs.
16. Mostofi FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumours. International Classification of Tumours, no 10.
17. Lopez-Beltran A, Cheng L. Stage pT1 bladder carcinoma: diagnostic criteria, pitfalls and prognostic significance. Pathology 2003 35 : 484 491
18. Mahmud SM, Fong B, Fahmy N, Tanguay S, Aprikian AG. Effect of preoperative delay on survival in patients with bladder cancer undergoing cystectomy in Quebec: a population based study. J Urol 2006 175 : 78 83
19. Chang SS, Hassan JM, Cookson MS, Wells N, Smith JA. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol 2003 170 : 1085 1087
20. Witjes JA, Kiemeney LA, Schaafsma HE, Debruyne FM. The influence of review pathology on study outcome of a randomized multicentre superficial bladder cancer trial. Members of the Dutch South East Cooperative Urology Group. Br J Urol 1994 73 : 172 176
21. Abel PD, Henderson D, Bennett MK, Hall RR, Williams G. Differing interpretations by pathologists of the pT category and grade of transitional cell cancer of the bladder. Br J Urol 1988 62 : 339 342
22. Van der Meijden A, Sylvester R, Collette L, Bono A, Ten Kate F. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials. J Urol 2000 164 : 1533 1537
23. Denzinger S, Fritsche HM, Otto W, Blana A, Wieland WF, Burger M. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol 2008 53 : 146 152
24. Mungan NA, Aben KK, Schoenberg MP et al. Gender differences in stage-adjusted bladder cancer survival. Urology 2000 55 : 876 880
25. Horstmann M, Witthuhn R, Falk M, Stenzl A. Gender-specific differences in bladder cancer: a retrospective analysis. Gend Med 2008 5 : 385 394
26. Saint F, Patard JJ, Maille P et al. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer. J Urol 2002 167 : 364 367